Fate Therapeutics, Inc.
FATEFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
14
Cost of Revenue
0
Gross Profit
14
Gross Margin
100.0%
Operating Income
-210
Operating Margin
-1542.6%
Net Income
-186
Net Margin
-1366.5%
EPS (Basic)
$-1.64
EPS (Diluted)
$-1.64
EBITDA
-177
EBITDA Margin
-1295.4%
2023
12/31/2023
Revenue
64
Cost of Revenue
157
Gross Profit
-94
Gross Margin
-147.4%
Operating Income
-191
Operating Margin
-299.9%
Net Income
-161
Net Margin
-253.3%
EPS (Basic)
$-1.64
EPS (Diluted)
$-1.64
EBITDA
-172
EBITDA Margin
-271.1%
2022
12/31/2022
Revenue
96
Cost of Revenue
14
Gross Profit
83
Gross Margin
85.7%
Operating Income
-308
Operating Margin
-320.2%
Net Income
-282
Net Margin
-292.5%
EPS (Basic)
$-2.91
EPS (Diluted)
$-2.91
EBITDA
-295
EBITDA Margin
-305.9%
2021
12/31/2021
Revenue
56
Cost of Revenue
6
Gross Profit
50
Gross Margin
89.5%
Operating Income
-217
Operating Margin
-388.6%
Net Income
-212
Net Margin
-379.9%
EPS (Basic)
$-2.24
EPS (Diluted)
$-2.24
EBITDA
-211
EBITDA Margin
-378.1%
2020
12/31/2020
Revenue
31
Cost of Revenue
126
Gross Profit
-94
Gross Margin
-299.6%
Operating Income
-128
Operating Margin
-407.5%
Net Income
-173
Net Margin
-551.6%
EPS (Basic)
$-2.10
EPS (Diluted)
$-2.10
EBITDA
-125
EBITDA Margin
-397.7%